Seda Grigoryan1, Anca M Avram2, Adina F Turcu3. 1. Department of Internal Medicine, Michigan State University, East Lasing. 2. Department of Radiology. 3. Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: Ectopic adrenocorticotropic hormone (ACTH)-secreting tumors are commonly small, yet they often lead to fulminant forms of Cushing syndrome. High-resolution functional imaging modalities, such as [Ga]-DOTATATE, have been recently introduced in clinical practice for the identification of neuroendocrine tumors. In this review, we focus on the performance of [Ga]-DOTATATE as a tool for localizing primary and metastatic sources of ectopic Cushing syndrome (ECS). RECENT FINDINGS: Prompt surgical removal of ectopic ACTH-secreting tumors is the mainstay of therapy in patients with ECS. Detecting such tumors with conventional cross-sectional imaging is often unsuccessful, owing to their small size. [Ga]-DOTATATE has been approved in 2016 by the Federal Drug Administration for imaging well differentiated neuroendocrine tumors. Data regarding the performance of [Ga]-DOTATATE for detecting ectopic ACTH-secreting tumors remain limited, in part owing to the recent introduction of this imaging modality in clinical practice, and in part because of the low prevalence of ECS. Nevertheless, [Ga]-DOTATATE has been reported to be useful in identifying primary and metastatic ectopic ACTH-secreting lesions that were not apparent on other imaging studies, impacting the clinical care of many patients with ECS. SUMMARY: [Ga]-DOTATATE-based imaging, which targets the somatostatin receptors abundantly expressed in neuroendocrine tumors, has generally high, although variable resolution in detecting the source(s) of ECS.
PURPOSE OF REVIEW: Ectopic adrenocorticotropic hormone (ACTH)-secreting tumors are commonly small, yet they often lead to fulminant forms of Cushing syndrome. High-resolution functional imaging modalities, such as [Ga]-DOTATATE, have been recently introduced in clinical practice for the identification of neuroendocrine tumors. In this review, we focus on the performance of [Ga]-DOTATATE as a tool for localizing primary and metastatic sources of ectopic Cushing syndrome (ECS). RECENT FINDINGS: Prompt surgical removal of ectopic ACTH-secreting tumors is the mainstay of therapy in patients with ECS. Detecting such tumors with conventional cross-sectional imaging is often unsuccessful, owing to their small size. [Ga]-DOTATATE has been approved in 2016 by the Federal Drug Administration for imaging well differentiated neuroendocrine tumors. Data regarding the performance of [Ga]-DOTATATE for detecting ectopic ACTH-secreting tumors remain limited, in part owing to the recent introduction of this imaging modality in clinical practice, and in part because of the low prevalence of ECS. Nevertheless, [Ga]-DOTATATE has been reported to be useful in identifying primary and metastatic ectopic ACTH-secreting lesions that were not apparent on other imaging studies, impacting the clinical care of many patients with ECS. SUMMARY:[Ga]-DOTATATE-based imaging, which targets the somatostatin receptors abundantly expressed in neuroendocrine tumors, has generally high, although variable resolution in detecting the source(s) of ECS.
Authors: Przemysław Witek; Joanna Witek; Grzegorz Zieliński; Zbigniew Podgajny; Grzegorz Kamiński Journal: Neuro Endocrinol Lett Date: 2015 Impact factor: 0.765
Authors: G Parenti; R Nassi; S Silvestri; S Bianchi; A Valeri; G Manca; S Mangiafico; F Ammannati; M Serio; M Mannelli; A Peri Journal: J Endocrinol Invest Date: 2006-02 Impact factor: 4.256
Authors: Karel Pacak; Ioannis Ilias; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Lynnette K Nieman Journal: J Clin Endocrinol Metab Date: 2004-05 Impact factor: 5.958
Authors: Anne-Leen Deleu; Annouschka Laenen; Herbert Decaluwé; Birgit Weynand; Christophe Dooms; Walter De Wever; Sander Jentjens; Karolien Goffin; Johan Vansteenkiste; Koen Van Laere; Paul De Leyn; Kristiaan Nackaerts; Christophe M Deroose Journal: EJNMMI Res Date: 2022-05-07 Impact factor: 3.434